These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

938 related items for PubMed ID: 19853192

  • 1. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
    Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E.
    Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
    Chen MK, Hung HF, Duffy S, Yen AM, Chen HH.
    J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
    Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V.
    Int J Technol Assess Health Care; 2008 Dec; 24(1):10-9. PubMed ID: 18218164
    [Abstract] [Full Text] [Related]

  • 4. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
    Wong G, Howard K, Webster A, Chapman JR, Craig JC.
    Transplantation; 2009 Apr 15; 87(7):1078-91. PubMed ID: 19352131
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of a cervical screening program with human papillomavirus vaccine.
    Sopina E, Ashton T.
    Int J Technol Assess Health Care; 2011 Oct 15; 27(4):290-7. PubMed ID: 21936972
    [Abstract] [Full Text] [Related]

  • 6. Integrating human papillomavirus vaccination in cervical cancer control programmes.
    Franco EL, Coutlée F, Ferenczy A.
    Public Health Genomics; 2009 Oct 15; 12(5-6):352-61. PubMed ID: 19684447
    [Abstract] [Full Text] [Related]

  • 7. [Cervical cancer prevention: the impact of HPV vaccination].
    Monsonégo J.
    Gynecol Obstet Fertil; 2006 Mar 15; 34(3):189-201. PubMed ID: 16529969
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM, van Ballegooijen M, Habbema JD.
    J Natl Cancer Inst; 2009 Aug 05; 101(15):1083-92. PubMed ID: 19571256
    [Abstract] [Full Text] [Related]

  • 9. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
    Adams M, Jasani B, Fiander A.
    Vaccine; 2007 Apr 20; 25(16):3007-13. PubMed ID: 17292517
    [Abstract] [Full Text] [Related]

  • 10. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.
    Vaccine; 2008 Jul 29; 26(32):4080-93. PubMed ID: 18550229
    [Abstract] [Full Text] [Related]

  • 11. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
    Tota J, Mahmud SM, Ferenczy A, Coutlée F, Franco EL.
    Sex Health; 2010 Sep 29; 7(3):376-82. PubMed ID: 20719230
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
    Bidus MA, Maxwell GL, Kulasingam S, Rose GS, Elkas JC, Chernofsky M, Myers ER.
    Obstet Gynecol; 2006 May 29; 107(5):997-1005. PubMed ID: 16648402
    [Abstract] [Full Text] [Related]

  • 13. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C.
    Vaccine; 2009 Oct 09; 27(43):6060-79. PubMed ID: 19647813
    [Abstract] [Full Text] [Related]

  • 14. Mathematical models of cervical cancer prevention in Latin America and the Caribbean.
    Goldie SJ, Diaz M, Constenla D, Alvis N, Andrus JK, Kim SY.
    Vaccine; 2008 Aug 19; 26 Suppl 11():L59-72. PubMed ID: 18945403
    [Abstract] [Full Text] [Related]

  • 15. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
    Gauthier A, Martín-Escudero V, Moore L, Ferko N, de Sanjosé S, Pérez-Escolano I, Catalá-López F, Ferrer E, Bosch FX.
    Eur J Public Health; 2008 Dec 19; 18(6):674-80. PubMed ID: 18641420
    [Abstract] [Full Text] [Related]

  • 16. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.
    Yamamoto N, Mori R, Jacklin P, Osuga Y, Kawana K, Shibuya K, Taketani Y.
    BJOG; 2012 Jan 19; 119(2):177-86. PubMed ID: 21794070
    [Abstract] [Full Text] [Related]

  • 17. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme.
    Dee A, Howell F.
    Eur J Public Health; 2010 Apr 19; 20(2):213-9. PubMed ID: 19864366
    [Abstract] [Full Text] [Related]

  • 18. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
    Schneider A, Schwarz TF, Hammerschmidt T, Siebert U.
    Med Klin (Munich); 2007 Jul 15; 102(7):515-23. PubMed ID: 17634869
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
    Thiry N, De Laet C, Hulstaert F, Neyt M, Huybrechts M, Cleemput I.
    Int J Technol Assess Health Care; 2009 Apr 15; 25(2):161-70. PubMed ID: 19366497
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.